[go: up one dir, main page]

NO20081454L - Met-kinaseinhibitorer - Google Patents

Met-kinaseinhibitorer

Info

Publication number
NO20081454L
NO20081454L NO20081454A NO20081454A NO20081454L NO 20081454 L NO20081454 L NO 20081454L NO 20081454 A NO20081454 A NO 20081454A NO 20081454 A NO20081454 A NO 20081454A NO 20081454 L NO20081454 L NO 20081454L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
met kinase
met
cancer
salts
Prior art date
Application number
NO20081454A
Other languages
English (en)
Inventor
David Kent Williams
John S Tokarski
Xiao Tao Chen
Robert M Borzilleri
Robert F Kaltenbach
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20081454L publication Critical patent/NO20081454L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser som har formel I eller II: omfattende salter derav, og metoder for anvendelse av dem for behandling av kreft.
NO20081454A 2005-09-30 2008-03-25 Met-kinaseinhibitorer NO20081454L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72208905P 2005-09-30 2005-09-30
US11/529,875 US7547782B2 (en) 2005-09-30 2006-09-28 Met kinase inhibitors
PCT/US2006/038216 WO2007041379A1 (en) 2005-09-30 2006-09-29 Met kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20081454L true NO20081454L (no) 2008-04-22

Family

ID=37547515

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081454A NO20081454L (no) 2005-09-30 2008-03-25 Met-kinaseinhibitorer

Country Status (5)

Country Link
US (1) US7547782B2 (no)
EP (1) EP1937682B1 (no)
JP (1) JP2009510113A (no)
NO (1) NO20081454L (no)
WO (1) WO2007041379A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101365676B (zh) * 2005-10-07 2013-09-11 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
US7723330B2 (en) 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
WO2008079294A1 (en) * 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
US7687522B2 (en) 2006-12-20 2010-03-30 Amgen Inc. Substituted pyridines and pyrimidines and their use in treatment of cancer
EP2778155A1 (en) 2007-01-31 2014-09-17 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
EP2125819B1 (en) * 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
ES2470341T3 (es) * 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
WO2008141130A1 (en) * 2007-05-11 2008-11-20 Kosan Biosciences, Inc. Process for the preparation of epothilones
US8030503B2 (en) 2007-05-11 2011-10-04 Kosan Biosciences Incorporated Process for the preparation of epothilones
CA2694499A1 (en) * 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
JP2010538094A (ja) * 2007-09-06 2010-12-09 アレイ バイオファーマ、インコーポレイテッド チロシンキナーゼ阻害剤としてのピラゾロピリジン類
EP2215089B1 (en) 2007-11-02 2012-06-27 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b]pyridine-4-yl]-phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
ES2531396T3 (es) 2008-01-23 2015-03-13 Bristol Myers Squibb Co Proceso para preparar compuestos de piridinona
EP2318407B1 (en) 2008-07-23 2013-01-02 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
CA2731498A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011837A1 (en) * 2008-07-24 2010-01-28 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2010017350A1 (en) * 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
EP2427464A1 (en) 2009-05-06 2012-03-14 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
IL302896A (en) 2009-10-06 2023-07-01 Millennium Pharm Inc Heterocyclic compounds useful as pdk1 inhibitors
CN102858769A (zh) 2010-01-27 2013-01-02 沃泰克斯药物股份有限公司 吡唑并吡啶激酶抑制剂
CA2787079A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
JP2013518114A (ja) 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾロピリミジンキナーゼ阻害剤
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
JP2014532060A (ja) 2011-10-03 2014-12-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 癌を治療するためのピロロピリミジン化合物
KR20150018789A (ko) 2012-05-22 2015-02-24 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 암의 치료를 위한 피리미딘 화합물
CN108948043B (zh) 2012-10-12 2021-05-04 埃克塞里艾克西斯公司 制备用于治疗癌症的化合物的新型方法
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
JP2017500362A (ja) * 2013-12-26 2017-01-05 イグナイタ インコーポレイテッド ピラゾロ［１，５−ａ］ピリジン誘導体およびその使用方法
US20150291609A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrimidine compounds
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
JP7191298B2 (ja) 2017-04-26 2022-12-19 バジリア・ファルマスーチカ・インターナショナル・アーゲー，アルシュヴィル フラザノベンズイミダゾール類及びその結晶形の調製方法
CN110218205B (zh) * 2019-07-05 2022-04-05 辽宁大学 含吡啶结构的2,4-二芳氨基嘧啶类衍生物及其应用
KR20230170039A (ko) 2021-04-13 2023-12-18 뉴베일런트, 아이엔씨. Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3464368D1 (de) 1983-03-09 1987-07-30 Beecham Group Plc Anti-inflammatory pyrazolo pyridines
EP0151962A3 (en) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
GB8404584D0 (en) 1984-02-22 1984-03-28 Beecham Group Plc Compounds
IE904346A1 (en) 1989-12-04 1991-06-05 Searle & Co IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF¹NEUROTOXIC INJURY
GB9312891D0 (en) 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
SI0907650T1 (en) 1996-06-27 2003-06-30 Janssen Pharmaceutica N.V. N- 4-(heteroarylmethyl)phenyl)-heteroarylamines
JP4633925B2 (ja) 1998-05-08 2011-02-16 スミスクライン ビーチャム ピー エル シー フェニル尿素およびフェニルチオ尿素誘導体
JP2002534446A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー ４′ヘテロアリールジアリールアミン
JP2000212141A (ja) * 1999-01-13 2000-08-02 Warner Lambert Co ジアリ―ルアミン
DE60042620D1 (de) 1999-05-21 2009-09-03 Bristol Myers Squibb Co Pyrrolotriazine als Kinase Hemmer.
WO2001057040A1 (en) 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
DE60106022T2 (de) 2000-06-06 2006-03-09 Pfizer Products Inc., Groton Thiophenverbindungen zur verwendung als antikrebsmittel
EP1363910B1 (en) 2000-11-17 2006-03-01 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
EP1372654A4 (en) * 2001-04-06 2007-10-03 Smithkline Beecham Corp QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
GB0126902D0 (en) 2001-11-08 2002-01-02 Novartis Ag Organic compounds
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
PL373371A1 (en) 2002-04-23 2005-08-22 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
WO2005021554A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
EP1677791A4 (en) 2003-10-31 2007-08-15 Takeda Pharmaceutical NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS

Also Published As

Publication number Publication date
JP2009510113A (ja) 2009-03-12
US20070078140A1 (en) 2007-04-05
EP1937682B1 (en) 2015-08-12
EP1937682A1 (en) 2008-07-02
US7547782B2 (en) 2009-06-16
WO2007041379A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
NO20081454L (no) Met-kinaseinhibitorer
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
NO20080965L (no) Cykloheksylaminisokinolonderivater som Rho-kinaseinhibotorer
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
NO20080150L (no) Inhibitorer av AKT-aktivitet
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
NO20092569L (no) Inhibitorer av Akt-aktivitet
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
WO2007079164A3 (en) Protein kinase inhibitors
NO20083267L (no) Azaindole inhibitorer av aurora kinaser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application